Clinical Trials » Stargardt Disease
Gene Therapy for Stargardt Disease (ABCA4 Mutations): Oxford Biomedica
|
RECRUITING Description: Oxford BioMedica, a gene therapy company in the U.K., has launched a Phase I/IIa clinical trial of its StarGen™ gene therapy for people with Stargardt disease. The treatment employs the company’s proprietary LentiVector® platform technology for the delivery of a corrective ABCA4 gene to the retina. The company is now conducting the trial at Oregon Health and Science University (Portland, Oregon), and is planning to begin a human study soon at Centre Hospitalier Nationale D’Opthalmologie des Quinze-Vingts (Paris, France). As many as 28 participants will be enrolled in the study. Three dose levels of the treatment will be evaluated for safety, tolerability and biological activity. The clinical trial was made possible by preclinical research funded by the Foundation Fighting Blindness. Trial Status: Recruiting Partial List of Participation Criteria:
David Wilson, M.D. (503) 494-3795 Casey Eye Institute, Oregon health & Science University Portland, Oregon 97239 Jose Sahel, M.D., Ph.D, Centre Hospitalier Nationale d'Ophthalmologie des Quinze-Vingts Paris, France, 75571 Articles: Gene Therapy Clinical Trial for Stargardt Disease to Begin This Year New Investment to Boost Gene Therapy Development Additional Information: StarGen clinical trial listing on ClinicalTrials.gov |
